Denali Therapeutics Chief Medical Officer Chin Peter Scott sold 1,654 shares at $22.29 per share on 2026-09-04. He retained 204,538 shares, and the transaction represented about 0.8% of his prior holding, making it a partial reduction rather than an exit for investors tracking insider ownership.

Key Highlights

  • Chin Peter Scott owned 204,538 Denali Therapeutics shares after the transaction.
  • The sale represented about 0.8% of his prior shareholding.
  • The transaction carried code S and took place on 4 September 2026.

Denali Therapeutics Inc. (NASDAQ: DNLI) Chief Medical Officer Chin Peter Scott sold 1,654 shares at $22.29 per share. The transaction occurred on 4 September 2026.

CMO Sale Leaves 204,538 Shares

Scott’s transaction carried SEC transaction code S. His reported position after the sale stood at 204,538 Denali Therapeutics shares. The transaction was at $22.29 per share. Scott is the company’s Chief Medical Officer.

Sale Covered 0.8% of Prior Holding

The post-transaction balance is 204,538 shares. The sold block represented about 0.8% of Scott’s prior holdings. The 0.8% figure refers to the transaction’s size against his prior shareholding, while 204,538 shares is the balance reported afterward. Transaction code S denotes an open-market or private sale.